Exploring Different Approaches to Identify & Engineer Out Fusion Proteins’ Immunogenicity & Toxicity

7:45 am Registration & Morning Coffee

8:45 am Chair’s Opening Remarks

  • Medha Tomlinson Director & Head Therapeutic Generation & Screening, Global Biologics, Takeda Pharmaceutical Co. Ltd.

9:00 am Developing Scalable Engineering Techniques to Improve Drug Safety & Maintain Efficacy


  • Considering a case study where small-scale fusion protein engineering was optimized to be scalable
  • Understanding the key design decisions that enabled this
  • Outlining how to predict the scalability of approaches

9:30 am Engineering Novel Antibody Fusion Proteins for Cancer Immunotherapy VIRTUAL

  • Christian Klein Head of Oncology Programs & Department & Cancer Immunotherapy Discovery , Distinguished Scientist, Roche


  • Engineering and preclinical properties of the novel antibody fusion proteins FAP-4-1BBL, CD19-4-1BBL
  • Design and preclinical properties of the novel PD-1 cis-targeted PD1-IL2v immunocytokine
  • Application for cancer immunotherapy

10:00 am Engineering Fusion Proteins to Reduce the Toxicity While Ensuring Appropriate Potency


  • Determining how changing binding affinity will affect toxicity and potency
  • Deciding the correct affinity for the drug target and disease indication 
  • Revealing decision making to determine the balance of reducing toxicity and effective potency 

10:30 am Morning Break & Speed Networking


Our speed networking is the ideal opportunity to get face-to-face time with many of the brightest minds working in fusion protein engineering and introduce yourself to the attendees that you would like to have more in-depth conversations with. Benchmark against industry leaders and establish meaningful business relationships to pursue for the rest of the conference and beyond.

11:30 am Modulating the Potency of Multispecific Fusion Proteins to Safely Accommodate Pro-Inflammatory Payloads

  • Brian Rabinovich Co-Founder & Chief Scientific Officer, Fuse Biotherapeutics, Inc


  • Using simultaneous adjustments of synaptic distance and apparent affinity to engineer multispecific fusion proteins with an array of potencies.
  • Choosing the functional attributes of an immune agonist fusion protein for addition of pro-inflammatory payloads
  • Developability considerations for complex multispecific fusion proteins incorporating inflammatory payloads

12:00 pm Multiplexed In Vivo Drug Discovery Using a Novel Protein Barcoding Technology

  • Pierce Ogden Co-Founder & Chief Scientific Officer, Manifold Bio


• Simultaneously determining biodistribution for pools of antibody molecules to engineer tumor and tissue targeting

• Examples of in vitro assays being poorly predictive of downstream in vivo results

• Examples from tumor-specific antibody engineering, blood-brain barrier (BBB) shuttle discovery

12:30 pm Using Fc-fusion Proteins to Activate NK Cells & Target Unwanted B Cell Responses

  • Basil Golding Director, Div of Plasma Protein Therapeutics, US Food & Drug Administration (FDA)


  • Showing Fc-fusion protein binding to FcgRIIIa (CD16) on NK cells
  • Demonstrating that activation of NK cells by an Fc-fusion protein requires secondary binding by the fusion protein
  • Using an Fc-fusion protein to target unwanted B cells

1:00 pm Networking Lunch

Validating Appropriate Engineering of Stable Fusion Proteins

2:00 pm Identifying Mutations to Improve Protein Stability for in Vivo Efficacy

  • Hilmar Ebersbach Senior Vice President - Antibody Development & Protein Engineering, Immunos Therapeutics


  • Determining which regions of the protein compromise stability using in silico tools and cell-based assays
  • Spotlighting modifications to improve the stability
  • Identifying commonalities across drug candidates to determine design rules

2:30 pm Spotlighting Complementary Assay Design to Assess the Immunosafety of a Novel TCR/anti-CD3 Fusion Protein


  • Developing a safety package in the absence of preclinical toxicology species
  • Recapping a case study of in vitro immunosafety assessment to assess activity and specificity and de-risk toxicity
  • Understanding how to ensure relevance of assays given differential behavior of proteins within each patient

3:00 pm Afternoon Networking Break

Discussing Modifications to Improve Expression & Add Functionality

3:45 pm Adding Therapeutic Functionality by Fusion of Diverse Protein Therapeutics: Synergy or Interference?

  • Gilad Kaplan Associate Director, Biologics Engineering, AstraZeneca


  • Recapping the development of a novel fusion protein therapeutic constructed from two diverse protein
  • Reflecting on the effects of fusion by comparing the fusion protein to its individual components for desired properties
  • Considering the path forward for similar fusion proteins

4:15 pm Protein Engineering Using Novel Chemical Methods to Access PD1-based Immunocytokines

  • Arnaud Goepfert Associate Director - Protein Sciences, Bright Peak Therapeutics


  • Generating immunocytokines through site-specific chemical conjugation of cytokine to “off-the-shelf” human IgG antibodies
  • Exploring PD1-based immunocytokines to induce potent antitumor immune response through orthogonal mechanisms of action
  • Functional characterization data of PD1-based immunocytokines

4:45 pm Chair’s Closing Remarks

  • Medha Tomlinson Director & Head Therapeutic Generation & Screening, Global Biologics, Takeda Pharmaceutical Co. Ltd.

5:00 pm End of Conference Day One

5:15 pm Drinks Reception Hosted By Bionova Scientific